Souhir Belloumi – Antibiotics – Best Researcher Award

Souhir Belloumi - Antibiotics - Best Researcher Award

Faculty of Sciences of Tunis and Center of Biotechnology of Borj Cedria - Tunisia

AUTHOR PROFILE

SCOPUS

🌟 INTRODUCTION TO ANTIBIOTICS RESEARCH EXCELLENCE

Souhir Belloumi is a dedicated junior researcher in Biological Sciences with a robust foundation in medical biotechnology, food preservation, and molecular biology. Her academic and professional trajectory reveals an intense focus on bioactive compounds, environmental applications, and especially the antimicrobial properties of essential oils as natural Antibiotics. Souhir has persistently explored how plant-derived substances function as sustainable and potent alternatives to conventional Antibiotics, particularly within the poultry and food industries. Her passion for Antibiotics stems from her early research days, where she discovered a unique niche between traditional botanical medicine and modern biochemical sciences. This interdisciplinary approach is central to her work, allowing her to contribute meaningful insights into the efficacy and shelf-life improvement of natural preservatives. With numerous scientific publications addressing the antibacterial, antifungal, and antioxidant properties of plant extracts, Souhir continually emphasizes the public health impact of Antibiotics derived from nature. Her contributions extend beyond lab-based experiments—she has worked with international institutions and industrial partners, reinforcing the applicability of her research. Through strategic innovation in essential oil chemistry and Antibiotics formulation, Souhir Belloumi demonstrates leadership in developing biopreservatives that serve both environmental and human health agendas, pushing the boundaries of what Antibiotics research can achieve in the 21st century.

📚 EARLY ACADEMIC PURSUITS IN ANTIBIOTICS SCIENCE

Souhir Belloumi’s academic journey into the field of Antibiotics began with a Bachelor's in Medical Biotechnology focused on Molecular Engineering from the University of Tunis El-Manar. Her early exposure to molecular microbiology and diagnostic kit development at the Pasteur Institute in Tunisia gave her foundational knowledge in DNA/RNA extraction, PCR techniques, and vaccine research, which are essential pillars in Antibiotics discovery and delivery. During her dual Master’s programs in Environment Biomonitoring and Biological Sciences, she developed a keen interest in the intersection of environmental factors and microbial resistance, particularly as it applies to naturally occurring Antibiotics in plant systems. Her PhD research at the University of Tunis El-Manar further honed her focus on the biological effects of essential oils, where she pioneered analytical techniques using LC-MS/MS to characterize plant compounds for Antibiotics potential. Her academic success was marked by hands-on research that continually returned to the central theme of natural Antibiotics, culminating in advanced knowledge of their chemical composition, antibacterial mechanisms, and preservation roles. These formative experiences shaped Souhir’s vision of advancing global health through sustainable Antibiotics, fusing molecular biology with nature’s own antimicrobial arsenal. Her education laid the groundwork for innovative, translational Antibiotics research.

🧪 PROFESSIONAL ENDEAVORS IN ANTIBIOTICS INNOVATION

Souhir Belloumi’s professional trajectory demonstrates her deep commitment to advancing Antibiotics research, particularly through applied biotechnology and food science. As a research scientist at the Laboratory of Bioactive Substances at the Center of Biotechnology of Borj-Cedria, she led studies focused on isolating bioactive compounds and testing their Antibiotics capabilities, especially within the poultry industry. Her collaboration with Poulina Holdings enabled the transition of lab-based discoveries into scalable industrial applications, offering natural Antibiotics alternatives that align with consumer safety and environmental responsibility. During her tenure as a research intern at the University of Pisa’s Department of Pharmacy, she worked on cutting-edge compound identification using LC-MS/MS, contributing to the broader pharmacognosy field and enhancing understanding of plant-derived Antibiotics. Her international experience bolstered her analytical skills and exposed her to interdisciplinary perspectives on Antibiotics efficacy. In every professional role, whether in Tunisia or abroad, Souhir maintained a steadfast focus on developing efficient, eco-friendly Antibiotics solutions that tackle microbial resistance without contributing to chemical pollution. Her contributions also span virology, environmental microbiology, and food analysis—each reinforcing the central role of Antibiotics in human and animal health. Her work not only bridges disciplines but redefines the role of natural Antibiotics in global antimicrobial strategies.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ANTIBIOTICS

Souhir Belloumi’s research contributions focus predominantly on the development and evaluation of bioactive compounds as viable Antibiotics alternatives. She has co-authored multiple peer-reviewed articles analyzing the antimicrobial and antioxidant potentials of essential oils such as Schinus molle and Tetraclinis articulata, exploring their synergy and effectiveness against various foodborne pathogens. These studies demonstrated how plant-derived Antibiotics can extend shelf life, maintain food safety, and combat resistant strains. Her work has gone beyond identification, venturing into the mechanistic pathways of how these Antibiotics act on microbial cells. Souhir’s focus on fractionation, compound purification, and chemical profiling via GC-MS and LC-MS/MS tools has made her a leading figure in natural Antibiotics analysis. Furthermore, her interdisciplinary methodology integrates food chemistry, microbiology, and immunology, emphasizing how natural preservatives can act as potent Antibiotics. By blending sensory evaluation with microbial inhibition assays, she provides a comprehensive approach to natural preservative development. Her research significantly contributes to the growing discourse on antimicrobial resistance, offering a nature-based solution. Through her dedication to Antibiotics innovation, she has helped establish evidence-based practices for utilizing essential oils in both medical and food-related applications, ensuring a sustainable and health-conscious future grounded in natural Antibiotics research.

🏅 ACCOLADES AND RECOGNITION IN ANTIBIOTICS SCIENCE

Souhir Belloumi’s work in Antibiotics research has garnered increasing recognition, particularly in international scientific circles focused on food safety and natural therapeutics. Her publication in Food Chemistry on essential oils as chicken meat preservatives is widely cited, highlighting her critical role in the advancement of natural Antibiotics applications. Her collaborative efforts with national and international laboratories have been praised for their methodological rigor and relevance in the context of antimicrobial resistance. Souhir has completed multiple prestigious certifications, including Statistical Analysis and QSE System Management, further solidifying her technical and regulatory expertise within the Antibiotics field. Her participation in the GIZ Master-Class in Germany demonstrates her leadership potential in managing interdisciplinary research on water and health sciences, closely related to microbial control via Antibiotics. These experiences have strengthened her capacity to act as a global voice in antimicrobial innovation. She is often acknowledged for integrating statistical modeling with chemical and microbiological evaluation to validate the efficacy of new Antibiotics solutions. In every professional development endeavor, the common thread is her emphasis on effective, safe, and environmentally sustainable Antibiotics technologies. Her awards and recognitions underscore her role as an emerging leader in natural Antibiotics discovery and deployment for both public health and industrial needs.

🌍 IMPACT AND INFLUENCE THROUGH ANTIBIOTICS RESEARCH

Souhir Belloumi’s influence extends across the domains of microbiology, biotechnology, and environmental health, all rooted in the powerful application of Antibiotics derived from natural sources. Her interdisciplinary research has impacted food preservation practices by introducing natural Antibiotics as effective alternatives to synthetic chemical preservatives. This has vast implications for reducing antimicrobial resistance globally. By collaborating with academic institutions, industrial sectors, and research labs in Tunisia and Europe, Souhir has fostered knowledge exchange that drives innovation in natural Antibiotics. Her mentoring of peers and sharing of experimental design insights has inspired a new generation of scientists to pursue research focused on sustainable Antibiotics. The broader health community benefits from her findings, especially in regions vulnerable to foodborne illness and limited pharmaceutical access. Her advocacy for integrating essential oils into public health frameworks contributes to national discussions on safe Antibiotics use in agriculture and food production. In scholarly forums and industry settings, Souhir promotes the role of bio-based Antibiotics in achieving both food security and antimicrobial stewardship. Her contributions continue to shape policy, inspire innovation, and enhance global understanding of natural Antibiotics as not just alternatives—but as necessities—in the fight against microbial threats.

🧬 LEGACY AND FUTURE CONTRIBUTIONS IN ANTIBIOTICS SCIENCE

Looking ahead, Souhir Belloumi envisions a future where Antibiotics derived from natural sources are central to global antimicrobial policy, sustainable agriculture, and health innovation. Her legacy is already taking form through her influential publications, global collaborations, and a clear focus on integrating essential oils and botanical extracts into mainstream Antibiotics strategies. With antimicrobial resistance posing a growing global threat, she plans to extend her research to cover synergistic formulations that enhance the potency of plant-based Antibiotics while minimizing cytotoxicity and side effects. Her next frontier includes exploring nanotechnology for enhanced delivery of Antibiotics compounds, potentially revolutionizing how infections are managed in both humans and animals. She is committed to educating future scientists, advocating for environmentally conscious Antibiotics development, and influencing health policies that embrace nature-based solutions. Through continuous innovation, publication, and public engagement, Souhir aims to establish international research platforms that prioritize natural Antibiotics over synthetic alternatives. Her enduring goal is to ensure that global communities, especially in the Global South, have access to affordable, effective, and sustainable Antibiotics. This vision cements her status as a pioneer in shaping a future where Antibiotics are no longer pollutants but protectors—rooted in nature, validated by science, and embraced by society.

NOTABLE PUBLICATION

  • Title: Combined essential oils as natural chicken meat preservatives: chemical composition, biological activities, synergy and shelf-life extension potential
    Authors: (Not fully listed in your message – please provide full author list or upload the article if you have it)
    Journal: Food Chemistry
    Year: 2025

ADELAIDA LAMAS FERREIRO – Antibiotic – Best Researcher Award

ADELAIDA LAMAS FERREIRO - Antibiotic - Best Researcher Award

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL. UNIVERSIDAD DE ALCALÁ. MADRID - Spain

AUTHOR PROFILE

GOOGLE SCHOLAR

INTRODUCTION TO A LIFETIME OF CARE 🌍

Dr. Adelaida Lamas stands as a remarkable figure in pediatric pulmonology, with an illustrious career centered on cystic fibrosis and the vital role of antibiotic therapies. Her clinical dedication has spanned more than two decades, particularly in respiratory medicine, where her expertise has reshaped the management of chronic infections in pediatric patients. She has led national efforts to refine antibiotic administration strategies in cystic fibrosis, directly influencing treatment protocols and patient outcomes. As the principal investigator at the Ramón y Cajal Institute for Health Research (IRYCIS), she spearheaded pioneering research in pulmonary microbiology, emphasizing the interplay between antibiotics and microbial resistance. Her advocacy for inhaled antibiotic therapies was instrumental in expanding access to life-prolonging treatments. From neonatology to intensive care, Dr. Lamas’s practice was always anchored in evidence-based medicine and ethical care. Her guidance as an expert with the Spanish Agency for Medicines and Health Products (AEMPS) further established her as a key voice in antibiotic evaluation and therapeutic positioning. Dr. Lamas’s work not only provided clinical clarity but also raised the standard of care across Europe. Through antibiotic-driven protocols, she has improved survival and quality of life for countless children. Her legacy begins here, with antibiotics at its heart.

EARLY ACADEMIC PURSUITS 📚

Adelaida Lamas’s journey into pediatric pulmonology and antibiotic therapeutics began with rigorous medical education at the Universidad de Valladolid, followed by her specialization at the Ramón y Cajal University Hospital. Her early academic focus was deeply rooted in pediatric respiratory pathophysiology, especially how antibiotics influence outcomes in cystic fibrosis and critical care. During her doctoral studies at the Universidad Autónoma de Madrid, her award-winning thesis examined sedation monitoring in critically ill children—a project intersecting with the timing and dosing of antibiotics in intensive care. Her early exposure to pediatric infectious disease units shaped her understanding of antibiotic resistance, prompting her to explore novel modes of delivery like aerosolized antibiotics for neonatal care. She also participated in cross-institutional training in Spain and the United States, further deepening her comprehension of global antibiotic stewardship. These foundational years fostered her lifelong commitment to evidence-based antibiotic applications. Recognizing the intricacies of microbiome-antibiotic interactions, she published early papers that addressed microbial colonization in children and the antibiotic responses in respiratory infections. Her training laid a powerful groundwork, allowing her to rise not just as a clinician, but as an antibiotic-conscious academic. This early pursuit set the tone for decades of innovation centered on children’s health and antibiotic optimization.

PROFESSIONAL ENDEAVORS 🏥

Dr. Adelaida Lamas’s professional career spans over 25 years, during which she served as a consultant pediatric pulmonologist at the Ramón y Cajal University Hospital. There, she became the national reference point for cystic fibrosis management and antibiotic strategy development. One of her hallmark contributions was leading the design and oversight of antibiotic protocols within Spain’s CF newborn screening programs. Her expertise expanded into bioethics and clinical decision-making, where she lectured extensively on the appropriate use of antibiotics in pediatric populations. As a member of multiple national and international ethics and clinical trial committees, she advocated for safe and timely antibiotic use in vulnerable children. She also evaluated pediatric antibiotics for the Spanish Agency for Medicines and Health Products (AEMPS), helping shape regulatory decisions. Through her work with the European clinical trials initiative (Conect4children), she contributed to global guidelines for pediatric antibiotic trials. Her involvement in therapeutic positioning reports for inhaled antibiotics like tobramycin and aztreonam further positioned her as a thought leader in this field. Her daily practice married compassion with precision, always anchored in responsible antibiotic use. Dr. Lamas not only advanced care but reshaped antibiotic discourse in pediatrics through decades of resolute clinical endeavor and scholarly service.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬

Throughout her prolific research career, Dr. Adelaida Lamas has published over 35 high-impact studies that focus on the intersection of pulmonary infections and antibiotic effectiveness in children with cystic fibrosis. Her groundbreaking work explored biofilm dynamics and how early antibiotic intervention alters pathogen colonization in respiratory tracts. She led key studies on the inhaled use of aztreonam, tobramycin, and other novel antibiotics that redefined how recurrent Pseudomonas aeruginosa infections are managed in chronic respiratory diseases. With collaborators from top European institutions, she investigated antibiotic heterogeneity and its role in resistance modulation. A strong advocate for combining antibiotics with probiotics, Dr. Lamas contributed to integrative therapeutic models that reduced microbial imbalance in CF patients. Her work in metaproteomics and gut microbiota establishment further emphasized the systemic effects of prolonged antibiotic use, positioning her as a forerunner in microbiome-aware therapy. Her leadership in randomized controlled trials ensured the ethical and scientific rigor of new antibiotic formulations. Her team’s publications are now widely cited in CF and pediatric pulmonology literature, influencing clinical guidelines across Europe. In short, her research has consistently pushed forward the boundaries of antibiotic science, ensuring that every child treated today benefits from decades of careful, research-driven innovation.

ACCOLADES AND RECOGNITION 🏅

Dr. Adelaida Lamas’s exceptional contributions to pediatric pulmonology and antibiotic therapies have garnered widespread recognition across clinical, academic, and governmental institutions. In 2006, her doctoral thesis received Spain’s “Dra. Juana Román First Prize,” the highest national honor in pediatric research. Her continued leadership earned her a permanent seat at the Spanish Agency for Medicines and Health Products (AEMPS), where she advised on pediatric antibiotic approvals. As principal investigator of several national and European antibiotic-related trials, she secured funding from global pharmaceutical leaders including Gilead and AstraZeneca. These trials revolutionized how antibiotic inhalation therapies are evaluated and prescribed for cystic fibrosis patients. Her recognition extended internationally when she was appointed as a key expert in pediatric pulmonology for Conect4children (c4c), shaping pan-European guidelines on antibiotic use in pediatric trials. Her teaching excellence earned her appointments at the Universidad de Alcalá and the International University of La Rioja, where she taught ethics in the use of antibiotics. Her voice is respected in editorial boards and therapeutic committees, particularly those focused on antibiotic innovation. In every honor received, the thread of her dedication to safe and effective antibiotic use in children remains central. Recognition of her work reflects the enduring impact of her antibiotic-focused legacy.

IMPACT AND INFLUENCE 🌐

The influence of Dr. Adelaida Lamas extends beyond the boundaries of her hospital and even her country. Her work in optimizing antibiotic protocols for pediatric pulmonology has inspired health policy reforms and research innovations globally. As one of the earliest adopters of inhaled antibiotic therapies, she helped bring these strategies from niche practices into standard protocols for cystic fibrosis patients. Her lectures on antibiotic resistance, ethical stewardship, and individualized therapy have been delivered across Europe and Latin America, where her voice commands respect and attention. Dr. Lamas’s influence is evident in international registries and multi-center trials, where her research and clinical models have been replicated. She has contributed significantly to the Spanish Federation of Cystic Fibrosis, promoting antibiotic literacy among patients and caregivers. Under her guidance, new pediatric pulmonologists have emerged, many of whom now lead CF units inspired by her antibiotic-focused methodologies. Her role in ethics committees ensured that antibiotic trials respect both safety and urgency—setting a benchmark for pediatric medicine. Dr. Lamas continues to shape antibiotic narratives through advisory boards, regulatory commissions, and academic forums. Her broad impact lies in proving that antibiotics, when used judiciously, are not just drugs—they are lifelines forged through science and compassion.

LEGACY AND FUTURE CONTRIBUTIONS 🌱

As Dr. Adelaida Lamas transitions from her active clinical roles, her legacy in pediatric pulmonology and antibiotic stewardship continues to flourish. She has trained countless professionals who now carry her antibiotic philosophy into new generations of care. Her published works serve as cornerstone references in antibiotic-based CF management and are embedded in Spain’s national respiratory care protocols. Beyond academia and hospitals, her advocacy has reached families and patients directly, helping demystify antibiotic use and resistance. Her future impact will unfold through her ongoing doctoral advisement roles, where she continues to guide research in hypertonic saline, probiotics, and next-generation antibiotics. She is also shaping ethical standards for emerging pediatric trials involving biologics and gene therapies, where the antibiotic baseline remains critical for infection control. With a strong foundation in both research and humanistic care, Dr. Lamas’s voice will remain central in regulatory debates and academic dialogues. Her legacy is proof that when science, ethics, and heart converge—especially around something as vital as antibiotics—the result is transformative. Looking ahead, she aims to contribute further by writing, mentoring, and consulting, all while ensuring that antibiotics remain a tool of precision, protection, and possibility for the children of tomorrow.

NOTABLE PUBLICATION

  • Title: Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey
    Authors: P. Mondejar-Lopez, E. Quintana-Gallego, R.M. Giron-Moreno, et al.
    Journal: Respiratory Medicine, Vol. 170, Article 106062, 2020

  • Title: Insulin resistance, β-cell dysfunction and differences in curves of plasma glucose and insulin in the intermediate points of the standard glucose tolerance test in adults with cystic fibrosis
    Authors: M.C. Megías, O.G. Albarrán, P.G. Vasco, A.L. Ferreiro, L.M. Carro
    Journal: Endocrinología y Nutrición (English Edition), Vol. 62(2), Pages 91–99, 2015

  • Title: A comprehensive evaluation of omega-3 fatty acid supplementation in cystic fibrosis patients using lipidomics
    Authors: Ó. Pastor, P. Guzmán-Lafuente, J. Serna, M. Muñoz-Hernández, A.L. Neyra, et al.
    Journal: The Journal of Nutritional Biochemistry, Vol. 63, Pages 197–205, 2019

  • Title: Protocol for the diagnosis and follow up of patients with cystic fibrosis
    Author: S. Gartner
    Journal: Anales de Pediatría (Barcelona, Spain: 2003), Vol. 71(3), Pages 250–264, 2009

  • Title: Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis
    Authors: L.M. Carro, A.L. Ferreiro, M.R. de Valbuena Maiz, C.W. Struwing, G.G. Álvarez, et al.
    Journal: Medicina Clínica, Vol. 138(2), Pages 57–59, 2012